A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension - BaxAsia

Inclusion Criteria

• Inclusion Criteria:
• • Male or female participants must be ≥ 18 years old.
• • Mean seated SBP on automated office blood pressure measurement (AOBPM) ≥ 140 mmHg at Screening.
• • Fulfil at least 1 of the following 2 criteria:
• a) uHTN subpopulation: have a stable regimen (≥ 4 weeks) of 2 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator.
• b) rHTN subpopulation: have a stable regimen (≥ 4 weeks) of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator.
• • Estimated glomerular filtration rate ≥ 45 mL/min/1.73m2 at Screening.
• • Serum potassium (K+) level ≥ 3.5 and < 5.0 mmol/L at Screening.• Mean seated SBP on AOBPM ≥ 135 mmHg at Baseline.
• Exclusion Criteria:
• • Mean seated SBP on AOBPM ≥ 170 mmHg.
• • Mean seated DBP on AOBPM ≥ 105 mmHg.
• • Serum sodium level (Na+) < 135 mmol/L at Screening.
• • Has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing’s syndrome, aortic coarctation.
• • NYHA functional heart failure class IV at Screening.